Literature DB >> 28862836

Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Ian Diner1, Jeromy Dooyema1, Marla Gearing1, Lary C Walker1, Nicholas T Seyfried1.   

Abstract

The benzothiazole-aniline derivative Pittsburgh Compound B (PiB) is the prototypical amyloid affinity probe developed for the in vivo positron emission tomography (PET) detection of amyloid beta (Aβ) deposits in Alzheimer's disease (AD). Specific high-affinity binding sites for PiB have been found to vary among AD cases with comparable Aβ load, and they are virtually absent on human-sequence Aβ deposits in animal models, none of which develop the full phenotype of AD. PiB thus could be an informative probe for studying the pathobiology of Aβ, but little is known about the localization of PiB binding at the molecular or structural level. By functionalizing the 6-hydroxy position of PiB with a PEG3 spacer and a terminal alkyne (propargyl) moiety, we have developed a clickable PiB compound that was derivatized with commercially available azide-labeled fluorophores or affinity-tags using copper-catalyzed azide-alkyne cycloaddition reactions, commonly referred to as "click" chemistry. We have determined that both the clickable PiB derivative and its fluorescently labeled conjugate have low nanomolar binding affinities for synthetic Aβ aggregates. Furthermore, the fluorescent-PiB conjugate can effectively bind Aβ aggregates in human AD brain homogenates and tissue sections. By covalently coupling PiB to magnetic beads, Aβ aggregates were also affinity-captured from AD brain extracts. Thus, the clickable PiB derivative described herein can be used to generate a wide variety of covalent conjugates, with applications including the fluorescence detection of Aβ, the ultrastructural localization of PiB binding, and the affinity capture and structural characterization of Aβ and other cofactors from AD brains.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28862836      PMCID: PMC5845826          DOI: 10.1021/acs.bioconjchem.7b00500

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  48 in total

1.  Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.

Authors:  Lee E Goldstein; Julien A Muffat; Robert A Cherny; Robert D Moir; Maria H Ericsson; Xudong Huang; Christine Mavros; Jennifer A Coccia; Kyle Y Faget; Karlotta A Fitch; Colin L Masters; Rudolph E Tanzi; Leo T Chylack; Ashley I Bush
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

2.  Amyloid-β Deposits Target Efficient Near-Infrared Fluorescent Probes: Synthesis, in Vitro Evaluation, and in Vivo Imaging.

Authors:  Hualong Fu; Peiyu Tu; Liu Zhao; Jiapei Dai; Boli Liu; Mengchao Cui
Journal:  Anal Chem       Date:  2016-01-12       Impact factor: 6.986

3.  Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates.

Authors:  Karin A Stephenson; Rajesh Chandra; Zhi-Ping Zhuang; Catherine Hou; Shunichi Oya; Mei-Ping Kung; Hank F Kung
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

4.  Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

Authors:  Andrew Lockhart; Liang Ye; Duncan B Judd; Andy T Merritt; Peter N Lowe; Jennifer L Morgenstern; Guizhu Hong; Antony D Gee; John Brown
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

Review 5.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

6.  Multiple ligand binding sites on A beta(1-40) fibrils.

Authors:  Harry LeVine
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease.

Authors:  Carol Man Gao; Alice Y Yam; Xuemei Wang; Erika Magdangal; Cleo Salisbury; David Peretz; Ronald N Zuckermann; Michael D Connolly; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow; Joseph P Fedynyshyn; Sophie Allauzen
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

View more
  3 in total

1.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

2.  Mapping the binding site topology of amyloid protein aggregates using multivalent ligands.

Authors:  Elena Sanna; Margarida Rodrigues; Steven G Fagan; Timothy S Chisholm; Klara Kulenkampff; David Klenerman; Maria Grazia Spillantini; Franklin I Aigbirhio; Christopher A Hunter
Journal:  Chem Sci       Date:  2021-06-07       Impact factor: 9.825

3.  Synthesis of Mono-N-Methyl Aromatic Amines from Nitroso Compounds and Methylboronic Acid.

Authors:  Silvia Roscales; Aurelio G Csákÿ
Journal:  ACS Omega       Date:  2019-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.